-Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation-Market for Topiramate in Oral Form is Greater than $800 million […]
LOS ANGELES, March 17, 2020 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development […]